OncoImmunology (Dec 2025)
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference
- Pierre-Antoine Laurent,
- Fabrice André,
- Alexandre Bobard,
- Desiree Deandreis,
- Sandra Demaria,
- Stephane Depil,
- Stefan B. Eichmüller,
- Cristian Fernandez-Palomo,
- Floris Foijer,
- Lorenzo Galluzzi,
- Jérôme Galon,
- Matthias Guckenberger,
- Kevin J. Harrington,
- Fernanda G. Herrera,
- Peter E. Huber,
- Antoine Italiano,
- Sana D. Karam,
- Guido Kroemer,
- Philippe Lambin,
- Carola Leuschner,
- Alberto Mantovani,
- Etienne Meylan,
- Michele Mondini,
- Mikael J. Pittet,
- Jean-Pierre Pouget,
- Jordi Remon,
- Claus S. Sørensen,
- Christos Sotiriou,
- Claire Vanpouille-Box,
- Ralph R. Weichselbaum,
- James W. Welsh,
- Laurence Zitvogel,
- Silvia C. Formenti,
- Eric Deutsch
Affiliations
- Pierre-Antoine Laurent
- Department of Radiation Oncology, Gustave Roussy, Villejuif, France
- Fabrice André
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Alexandre Bobard
- SIRIC EpiCURE, Gustave Roussy, Villejuif, France
- Desiree Deandreis
- Division of Nuclear Medicine, Gustave Roussy, Villejuif, France
- Sandra Demaria
- Department of Radiation Oncology, Weill Cornell Medicine, New-York, NY, USA
- Stephane Depil
- Cancer Research Center of Lyon, Centre Léon Bérard, Université Claude Bernard, Lyon, France
- Stefan B. Eichmüller
- Research Group GMP & T-cell therapy, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
- Cristian Fernandez-Palomo
- Institute of Anatomy, University of Bern, Bern, Switzerland
- Floris Foijer
- European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
- Lorenzo Galluzzi
- Department of Radiation Oncology, Weill Cornell Medicine, New-York, NY, USA
- Jérôme Galon
- INSERM, Laboratory of Integrative Cancer Immunology; Sorbonne Université; Sorbonne Paris Cité, Université de Paris, Paris, France
- Matthias Guckenberger
- Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
- Kevin J. Harrington
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, UK
- Fernanda G. Herrera
- Radiation Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland
- Peter E. Huber
- Department of Radio-oncology and Radiotherapy, University Hospital Heidelberg; Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany
- Antoine Italiano
- Department of therapeutic innovations (DITEP), Gustave Roussy, Villejuif, France
- Sana D. Karam
- Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Guido Kroemer
- Centre de Recherche des Cordeliers, Université de Paris Cité, Sorbonne Université, Paris, France
- Philippe Lambin
- Department of Precision Medicine, GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands
- Carola Leuschner
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Alberto Mantovani
- IRCCS Humanitas Research Hospital, Rozzano, MI, Italy
- Etienne Meylan
- Laboratory of Immunobiology, Department of Molecular Biology, Faculty of Sciences, Université Libre de Bruxelles, Bruxelles, Belgium
- Michele Mondini
- INSERM, U1030 “Molecular Radiotherapy and Therapeutic Innovations”, Gustave Roussy, Villejuif, France
- Mikael J. Pittet
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
- Jean-Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier (IRCM)INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France
- Jordi Remon
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
- Claus S. Sørensen
- Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark
- Christos Sotiriou
- Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium
- Claire Vanpouille-Box
- Department of Radiation Oncology, Weill Cornell Medicine, New-York, NY, USA
- Ralph R. Weichselbaum
- Department of Radiation and Cellular Oncology, Ludwig Center for Metastasis Research; University of Chicago, Chicago, IL, USA
- James W. Welsh
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Laurence Zitvogel
- ClinicObiome, Gustave Roussy, Villejuif, France
- Silvia C. Formenti
- Department of Radiation Oncology, Weill Cornell Medicine, New-York, NY, USA
- Eric Deutsch
- Department of Radiation Oncology, Gustave Roussy, Villejuif, France
- DOI
- https://doi.org/10.1080/2162402X.2024.2432726
- Journal volume & issue
-
Vol. 14,
no. 1
Abstract
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.
Keywords
